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Abstract
Background: Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare but extremely severe
cutaneous adverse drug reactions in which drug-specific associations with HLA-B alleles were described.
Objectives: To investigate genetic association at a genome-wide level on a large sample of SJS/TEN patients.
Methods: We performed a genome wide association study on a sample of 424 European cases and 1,881 controls
selected from a Reference Control Panel.
Results: Six SNPs located in the HLA region showed significant evidence for association (OR range: 1.53-1.74). The
haplotype formed by their risk allele was more associated with the disease than any of the single SNPs and was
even much stronger in patients exposed to allopurinol (ORallopurinol = 7.77, 95%CI = [4.66; 12.98]). The associated
haplotype is in linkage disequilibrium with the HLA-B*5801 allele known to be associated with allopurinol induced
SJS/TEN in Asian populations.
Conclusion: The involvement of genetic variants located in the HLA region in SJS/TEN is confirmed in European
samples, but no other locus reaches genome-wide statistical significance in this sample that is also the largest one
collected so far. If some loci outside HLA play a role in SJS/TEN, their effect is thus likely to be very small.
Background
Adverse drug reactions are a major public health issue
as they represent an important cause of morbidity and
mortality [1]. Skin lesions are frequent expressions of
adverse drug reactions with, for some drugs, up to 10%
of cutaneous reactions observed [2,3]. SJS and TEN are
severe cutaneous adverse reactions characterized by the
development of acute exanthema which progresses
towards limited (in SJS) or widespread (in TEN) blister-
ing and erosion of the skin and mucous membranes [4].
SJS and TEN are thus considered to be two different
forms of the same disease with TEN representing the
most severe form [5]. The incidence of SJS/TEN is esti-
mated to be of approximately 1-2 patients per million
individuals per year [6]. It is thus a very rare disease but
with a high morbidity and mortality (reaching up to
45% in TEN) that requires intensive treatment.
SJS/TEN is not associated with a single drug or a sin-
gle group of drugs but several different drugs have been
involved. A limited number of drugs however are more
often associated with the disease: antibacterial sulfona-
mides (especially sulfamethoxazole), allopurinol, which
is the most frequent drug involved [7], carbamazepine,
lamotrigine, phenobarbital, phenytoine, non-steroidal
anti-inflammatory drugs (NSAIDs) of the oxicam type
and neviparine [4,8]. Only a small number of individuals
exposed to these “highly suspected” drugs develop the
disease and a genetic susceptibility has been suggested
[9-12].
An association with HLA was reported more than 20
years ago [12,13]. More recently, studies in the Han Chi-
nese population have involved the HLA-B locus with
very strong drug-specific associations: the HLA-B*1502
allele was found in all carbamazepine-induced SJS/TEN
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patients [14] and the HLA-B*5801 in all allopurinol-
induced SJS/TEN patients [15]. An investigation of
HLA-B associations in European samples did not detect
the association between the HLA-B*1502 allele and car-
bamazepine-induced SJS/TEN but did report a strong
but not complete association between HLA-B*5801 and
the allopurinol-induced disease [16,17]. Furthermore, it
has also been suggested that HLA genetic predisposition
may not be the same for SJS and TEN and that it might
thus be important to take into account the disease
severity in association tests [18].
Apart from HLA, several other candidate genes have
been tested for association with SJS/TEN, mostly genes
involved in the immune response, in the inflammation
process or in drug metabolism [18-21]. However, no
association with these genes has been consistently found
and it has been suggested that rather than focusing on
candidate genes, a genome-wide association study might
provide more insights into the genetic susceptibility of
adverse drug reactions [21].
In the context of the RegiSCAR project (European
Registry of Severe Cutaneous Adverse Reactions to
Drugs and Collection of Biological Samples) DNA of
563 cases of SJS/TEN was collected. This is the largest
available sample of SJS/TEN patients in the world with
accurate medical information regarding the severity of
the disease and the history of drug intake. These
patients were genotyped at the Centre National de Gen-
otypage (CNG) using Illumina 317 K chips and a Gen-
ome Wide Association Study (GWAS) was conducted
against controls selected from the CNG European Refer-
ence Control Panel [22].
Methods
Patients
A total of 563 cases (226 males and 337 females, sex-
ratio = 0.67) were included in this study. They were col-
lected as part of the “European Registry of Severe Cuta-
neous Adverse Reactions” (RegiSCAR) (see http://
regiscar.uni-freiburg.de/) in six countries (Austria (1
case), France (184 cases), Germany (331 cases), Israel
(14), Italy (26) and The Netherlands (7)). All of them
had a diagnosis of SJS (268 cases, 48%), SJS/TEN over-
lap (181 cases, 32%) or TEN (114 cases, 20%) validated
as probable or definitive by the expert committee of
RegiSCAR blindly from information on drug exposure.
For each patient, written informed consent was
obtained and a blood sample was taken for genomic
DNA extraction that was carried out at the CEPH-Fon-
dation Jean Dausset (France) (http://www.cephb.fr) until
2005 and at the biobank of the CIC-Henri Mondor /
Créteil after 2005.
The 563 patients were genotyped on Illumina 317 K
chips in France at the CNG (http://www.cng.fr) for a
total of 318,127 SNPs (among which 309,091 were
located on autosomes). Stringent quality-control (QC)
was performed using Plink v1.06 [23] that led to the
exclusion of 68 out of the 563 cases for low genotyping
(MIND > 0.05) and 15,088 SNPs (14,343 autosomal
SNPs) for missing data (GENO > 0.05). After QC, a
total of 495 affected individuals were considered in the
analysis for whom genotypes on 303,039 SNPs (294,748
located on autosomes) were available. The total geno-
typing rate in these 495 remaining individuals was 0.95.
Controls
Controls were selected from the CNG European Refer-
ence Panel collected at the CNG [22]. This panel
includes 5,847 unrelated individuals from 13 European
countries who are all genotyped on Illumina 317 K
chips. Since patients collected as part of the RegiSCAR
project were mostly from France and Germany, we
decided to consider only the 1,881 individuals from the
Reference Control panel originating from these two
countries (653 from Germany and 1,228 from France).
Quality control and principal component analysis of
genotype data
A second quality control of the data was performed
where markers that were missing in more than 5% of
the controls or had significant different missing rates
between cases and controls were removed. A total of
25,834 autosomal markers were excluded.
To assess the level of population stratification in the
sample, a principal component analysis (PCA) was per-
formed using the genotypes of the 495 cases and 1,881
controls for a sub-panel of 35,232 markers obtained
after pruning based on linkage disequilibrium using
Plink (option indep-pairwise 50 5 0.1). The program
smartPCA from the Eigenstrat package [24,25] was used
with the default options. A total of 71 patients were
excluded from the study as they were found to be out-
liers. Those were mostly individuals with a suspected
African or Asian ancestry. Plots of the first two principal
components (PCs) are provided in Figure 1.
As shown in the flowchart in Figure 2, a total of
268,914 autosomal SNPs were kept for the association
testing in a sample of 424 SJS/TEN patients and 1,881
controls.
Drug exposure
Information on drug exposure was collected by inter-
viewing patients about their drug intakes and by con-
sulting medical records. Reactions were considered to be
potentially caused by allopurinol, carbamazepine or phe-
nytoin if the drug has been taken between 4 and 10
days before the onset of the disease and if the drug has
not been started more than 42 days before onset. This
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resulted in a group of 57 patients (13.4%) with poten-
tially allopurinol-induced reactions, a group of 25
patients (5.9%) with potentially carbamazepine-induced
reactions and a group of 19 patients (4.5%) with poten-
tially phenytoin-induced reactions. Because of the low
number in the latter two groups we decided to only
compare the allopurinol group and the group with other
drugs to the controls in this study. Note that because of
the stringent time criterion used to determine allopuri-
nol as culprit drug there might be some patients with
an allopurinol-induced reaction left in the group of
patients with a culprit drug other than allopurinol. For
this reason, this analysis was further enforced by an
additional analysis where any allopurinol exposed
patient (irrelevant of time of usage) was assigned to the
allopurinol group resulting in a higher sensitivity with
respect to allopurinol-induced reaction while the specifi-
city is decreased.
Association testing
Association was tested using the PC-corrected Armi-
tage-trend test implemented in Eigenstrat [24]. A sensi-
tivity analysis was performed to determine the number
of PCs that should be accounted for and we decided to
adjust only on the first two PCs (the genomic control
coefficient lambda [26] was 1.023 when adjusting on the
top 2 PCs, 1.019 when adjusting on the top 10 PCs and
1.016 when adjusting on the top 20).
Odds-ratios (OR) and confidence intervals of the dif-
ferent genotypes were computed using the logistic
regression model implemented in Plink v1.06 [23].
To study the influence of the drug involved in the dis-
ease, a second study was performed where the multino-
mial logistic model implemented in Stata v10 [27] was
used as in [28]. The disease status D was coded in 3
classes: 0 unaffected (controls), 1 affected with a sus-
pected allopurinol-induced disease, 2 affected with
another suspected drug induced disease. At each SNP,
an additive model was considered and two ORs were
computed to model the effect of the SNP among allo-
purinol-induced affected individuals (ORallopurinol) and
among other affected individuals (ORotherdrugs). The null
hypothesis tested was one of no effect of the SNP in any
of the strata, i.e. ORallopurinol = ORotherdrugs = 1. It was
tested using a 2 degrees-of-freedom chi-square test. The
significance of the difference between ORallopurinol and
ORotherdrugs was also tested in this model using the cor-
responding one degree-of-freedom chi-square test.
In the same way, a multinomial logistic model was
used to determine whether genetic differences exist
depending on the disease severity. A four class disease
status was used: 0 unaffected (controls), 1 SJS, 2 SJS/
TEN overlap and 3 TEN.
Furthermore, haplotype association was tested using
Plink v1.06 [23].
For all the logistic regression modelling and haplotype
association testing, an adjustment on the first two PCs
obtained from the PCA of the genotype data was used.
Results
The clinical details of the 424 patients remaining after
quality-control are summarized in Table 1: 61.3% are
female, 47.2% have a SJS phenotype, 34.4% a SJS/TEN
overlap phenotype and 18.4% a TEN phenotype. A
majority of the patients was sampled from France (110
patients) and Germany (277 patients). History of drug
intake was carefully monitored and a subgroup of 57
Figure 1 Plots of top two principal components for cases (in
red) and controls (in black).
Quality Check 
495 patients 294,748
SNPs
Exclusion of 
68 patients 
Exclusion of 
14,343 SNPs 
309,091
autosomal SNPs 
1,881 controls 
Comparison of 
missing rates 
Exclusion of 
25,834 SNPs 
495 patients 268,914
SNPs
1,881 controls 
Principal
Component 
Exclusion of 
71 patients 
424 patients 268,914
autosomal SNPs 
563 patients 
1,881 controls 
Figure 2 Flowchart summarizing the different steps of the
quality control of the data.
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patients (13.4%) with potentially allopurinol-induced
reactions was identified. There is no difference in phe-
notype distribution between males and females but
there are some differences depending on the drug and
the country where samples were collected. There is a
lack of TEN among allopurinol-induced patients (test of
homogeneity of the three disease forms in allopurinol
induced versus non-allopurinol induced partients: chi-
square = 7.89, p-value = 0.019) and a lack of TEN
among patients from Germany as compared to patients
from France (chi-square = 23.68, p-value = 7.2 10-6).
The two variables however are not independent since
allopurinol is more used in Germany than in some
other countries and in particular France.
For association testing, the 424 patients were com-
pared to the 1,881 controls from the reference panel ori-
ginating from France (1,228 individuals) and Germany
(653 individuals) who were also the closest controls to
the cases on the PCA plot (Figure 1). We then tested
each SNP for association controlling on the first two
PCs of the PCA using Eigenstrat [24]. Results are pre-
sented in Figure 3. One genome-wide significant signal
was detected in the MHC region on chromosome 6
where 6 SNPs showed False Discovery Rate adjusted q-
values below 5% (see Figure 4 and Table 2). The most
significant SNP, rs9469003, is located at position
31,515,807, ~85 kb upstream of the HLA-B locus and
has an OR of 1.73 (95%CI = [1.44;2.08]). The five other
SNPs are all located in a more telomeric region, 250 kb
apart from rs9469003, in between positions 31,114,834
and 31,250,224 (see Figure 5). There is very limited
Linkage Disequilibrium (LD) between these five SNPs
and the top one and the six SNPs defined 13 haplotypes
with a frequency of 1% or above. The haplotype CAC-
GAC formed by the risk allele at each locus showed the
strongest association with the disease with an OR of
2.84 (95%CI = [2.03; 3.98]) that is significantly higher
than the one observed for rs9469003 only. To dissect
further this haplotypic association, the haplotype condi-
tioning test implemented in Plink v1.06 was used and
we found that none of the 6 SNPs by itself has an inde-
pendent effect nor explains the haplotype association.
Table 1 Description of the sub-sample of 424 patients
selected for the analysis
Number of patients SJS SJS/TEN TEN Total
Total 200
(47.2%)
146
(34.4%)
78
(18.4%)
424
Females 124 89 47 260
(61.3%)
Allopurinol-
induced
33 21 3 57 (13.4%)
From France 41 32 37 110
(25.9%)
From Germany 145 97 35 277
(65.3%)
From Other
countries
14 17 6 37 (8.7%)
The number of patients (proportion of the total of 424 patients in percents)
with the different phenotypes is presented in the total sample, among the
female patients and as a function of the country where patients were
identified.
Figure 3 Results of the genome-wide association screen. The -log(p-value) of the PC-corrected Armitage-trend test implemented in
Eigenstrat are plotted for the 268,818 autosomal SNPs that passed the QC with the different colors representing the different chromosome. The
horizontal line represents the 10-6 p-value threshold that also corresponds to a False Discovery Rate q-value of 5%.
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Table 2 List of most significant SNPs associated with SJS/TEN
SNP Chr Position
Build 36
RiskAllele
(Other
Allele)
Risk Allele
Frequency
in Cases
Risk Allele
Frequency in
Controls
PC
corrected
Trend
testb
p-
valueb
q-
valuec
OddsRatiod 95%
CId
Pvalue
of HW
test
Annotationa
rs2844665 6 31114834 C (T) 0.72 0.62 26.46 2.69
10-7
1.48
10-2
1.54 1.30-
1.82
0.77 C6orf205
flanking_3UTR
rs3815087 6 31201566 A (G) 0.31 0.21 26.32 2.89
10-7
1.54
10-2
1.53 1.29-
1.80
0.08 PSORS1C1
UTR
rs3130931 6 31242867 C (T) 0.77 0.69 24.41 7.78
10-7
3.34
10-2
1.54 1.29-
1.84
0.66 POU5F1
Intron
rs3130501 6 31244432 G (A) 0.83 0.74 31.78 1.73
10-8
0.22
10-2
1.74 1.43-
2.13
0.59 POU5F1
Intron
rs3094188 6 31250224 A (C) 0.72 0.63 30.75 2.93
10-8
0.26
10-2
1.59 1.34-
1.88
0.06 POU5F1
Flanking_5UTR
rs9469003 6 31515807 C (T) 0.24 0.15 36.41 1.60
10-9
0.04
10-2
1.73 1.44-
2.08
0.003 HCP5
flanking_5UTR
a Annotations were obtained from the Illumina annotation file.
b Results obtained using the test implemented in Eigenstrat
c q-values (FDR adjusted p-values) were obtained by using the R package fdrtool [50].
d Results obtained using plink logistic regression test accounting for the top 2 PC.
A
B
Figure 4 Results of the association test on chromosome 6. A The -log(p-value) of the PC-corrected Armitage-trend test implemented in
Eigenstrat are plotted for the 18,1278 SNPs located on chromosome 6 as a function of their position on the chromosome in base pairs (Build
36). SNPs located in the HLA region are highlighted in red. B Detail of the association signals for the 706 SNPs located in the HLA region. The
horizontal line represents the 10-6 p-value threshold.
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Using a multinomial logistic regression approach, we
found that the association with haplotype CACGAC was
much stronger in the subgroup of patients with an allo-
purinol induced disease (ORallopurinol = 7.77, 95%CI =
[4.66; 12.98]) than in other patients (ORotherdrugs =
1.92, 95%CI = [1.40;2.64]). The equality of odds-ratio
(ORallopurinol = ORotherdrugs) was strongly rejected
(p = 6.56 × 10-7). Results were the same in France and
Germany a shown in Additional File 1 Tables S1 and S2.
To determine how much of the observed signal could
be explained by the known association between allopuri-
nol-induced SJS/TEN and HLA-B*5801, we took advan-
tage of the availability of HLA-B two-digit resolution
genotypes for 74 of the 424 patients [16]. Among the 74
HLA-B genotyped patients, 11 were carriers of an HLA-
B58 allele and had an allopurinol-induced disease. The
frequency of the CACGAC haplotype is increased in
HLA-B58 carriers as compared to non HLA-B58 carriers
(32.44% versus 10.44%, p-value of the test adjusted on
the top 2 PC = 0.0052) but the linkage disequilibrium is
not complete. Note however that given the small sample
size of HLA-B typed individuals, the power was quite
low to detect this difference (power of 60% at a type-
one error rate level of 5%).
Discussion
Discovering genes involved in severe cutaneous adverse
reactions and especially SJS/TEN is a major challenge
for pharmacogenetics as these reactions, when not fatal,
are a sword of Damocles for those who already had the
disease and fear to take any drug. Despite important
efforts, only genes located in the HLA region have been
identified so far. One possible explanation for this lack
of success is the limited sample sizes of patients
A
rs9469003
rs3815087
rs3130931 rs3130501
rs2844665 rs3094188
rs3130931 rs3130501rs3815087rs2844665 rs3094188 rs9469003
B
Figure 5 Association results in the 401 kb region encompassing the top six signals. A The -log(p-value) of the PC-corrected Armitage-
trend test are plotted against the chromosome 6 positions for the 126 SNPs located in the region. B Listing of genes located in this region
based on the HapMap web-browser.
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available. Indeed SJS/TEN is fortunately a very rare dis-
ease and in most studies, sample sizes rarely exceed one
or two hundreds of patients, making it difficult to inves-
tigate more than a few candidate genes. Through a col-
laborative effort, the RegiSCAR group was able to
collect detailed medical information and DNA of more
than half a thousand of patients from Europe who were
genotyped on Illumina 317 K chips. By comparing their
genotypes to the ones of 1,881 controls genetically
matched for the country of origin, we were able to
study the SJS/TEN association at a genome-wide level
on European samples. Apart from six SNPs located in
the HLA region, no other locus was found to be asso-
ciated with the disease at a high enough significance
level to ensure it is not false positive due to the multiple
tests performed. Sample sizes of half a thousand are not
enough to ensure a good power to detect common var-
iants with small effects (OR in the range between 1.1
and 1.3) similar to those identified in several common
diseases such as diabetes or different cancers [29] where
larger samples are easier to collect. However, given the
424 patients remaining after Quality Control, the study
was powerful enough to detect common variants with
modest effects (the power exceeded 80% to detect var-
iants with an allele frequency above 15% conferring ORs
above 1.7 under a multiplicative model). The fact that
only the HLA region is detected, suggests that there
might not be any other common variant that confer a
substantial increase in disease risk and could thus be of
interest as a predictive factor. These power computa-
tions might however be too optimistic as they are based
on the assumption that the same genetic variants might
be involved in cases of SJS/TEN associated to different
drugs. If we consider that there might exist some levels
of genetic heterogeneity depending on the drugs
involved as it is the case for HLA associations, the
power can be dramatically reduced. For example, con-
sidering only the 57 allopurinol-exposed cases, the
power to detect a variant of frequency 15% conferring
an OR of 2 is then only 5% at a nominal type-one error
rate value of 10-6. On the other hand, the power to
detect a similar effect than the one observed at
rs9469003 (i.e., risk allele of frequency of 15% with an
associated OR of ~4 among allopurinol-induced SJS/
TEN) is 99%, showing that the study was not underpow-
ered to detect strong effects even if they were restricted
to a small subset of patients.
It is true however that we might have missed some var-
iants with important effects, especially those with minor
allele frequencies below 5% that are not well covered by
SNP-chips and it could thus be of interest to investigate
the association with rare variants. If the “common dis-
ease-common variant hypothesis” was believed to explain
the susceptibility to multifactorial diseases [30,31], results
from GWAS have shown that common variants only
explain a minor part of most common disease heritabil-
ities. It has been suggested that rare variants could
explain at least part of this “missing heritability” and
indeed, rare variants have been found in several diseases
[32-36]. Interestingly these rare variants are often func-
tional variants with a direct impact on the protein func-
tionality and they usually confer a much stronger
increase in disease risk than common variants. They are
also more likely to be affected by some moderate levels
of negative selection [37,38]. For diseases such as adverse
drug reactions, it is not unlikely that the genes and var-
iants involved could be under selection. Indeed if most of
the drugs have been introduced too recently to be
directly responsible for selective pressures, they are often
derived from nutrients that have been consumed by
humans for a long time. Thus, genes involved in drug
metabolism can potentially be involved in natural selec-
tion and this was confirmed by previous studies [39-41].
However, the implication of drug metabolism genes in
SJS/TEN remains to be established.
Concerning the association with HLA detected in this
sample, we confirmed that it is drug-specific with the
strongest association found for the group of patients
where allopurinol is suspected to be the cause of the
disease. However the disease association was still detect-
able after exclusion of all patients exposed to allopurinol
(whether considered as causing the reaction or not) (OR
= 2.13, 95% CI = [1.41; 3.23]). This suggests that differ-
ent HLA alleles are probably involved depending on the
drug, and the 6 SNPs identified could be those that
were in linkage disequilibrium (LD) with several of these
HLA alleles. To further explore this hypothesis, we tried
to impute HLA-B genotypes from the SNP data [42] but
we were not successful because of the presence of multi-
ple rare alleles at this locus such as HLA-B58 itself that
is only present in one of the European families geno-
typed by de Bakker et al. [43] precluding the possibility
to find appropriate tags for this allele using this sample.
To overcome the problem, we tried to determine tag
SNPs using our own HLA-B genotyped sample that was
enriched in HLA-B58 but we did not find any SNP or
group of SNPs that was correlated enough with the
HLA-B58 allele (the maximum r2 value was below 20%).
This poor HLA-B tagging ability of the SNPs could cer-
tainly explain why the association found here in relation
with allopurinol is much weaker than the one reported
in studies on European samples using resolved HLA-B
alleles [16,44]. However, even in these two latter studies,
the association with HLA-B*5801 is much weaker than
the one found in Han Chinese [15] or Thai populations
[45] where all patients with allopurinol-induced SJS/
TEN are carriers of this allele. It is thus possible that
the HLA genetic determinants involved in SJS/TEN are
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not the HLA-B alleles themselves but some loci in LD
with them. Further studies in this genomic region would
certainly be necessary to better understand the mechan-
isms involved.
On a methodological point of view, this study illus-
trates how Reference Control Panels could be used to
test for association when only cases are genotyped. Only
patients were genotyped here and controls were selected
from the CNG European Control Panel [22] based on
their country of origin that was either France and Ger-
many, since those were the two main countries where the
cases come from. We also tried to use the whole panel of
controls and correct for population stratification using
Principal Component Analysis (PCA) and an adjustment
on up to 20 PCs instead of the 2 used here. We found
that including controls that were more genetically distant
to the cases does not really improve the signal in the
HLA region and instead could lead to false positive
results in other genomic regions. This is somewhat in
contradiction with the results recently reported by
Zhuang et al. [46] and will probably need to be further
investigated. We also used some alternative approaches
where controls were genetically matched to cases using
either a distance based on the identity by state as
described by Guan et al. [47] or a distance derived from
the top PCs of the PCA performed to identify axes of var-
iations similar to the one proposed by Luca et al. [48].
Tests accounting for the matching units were then per-
formed and we found that only the HLA region pointed
out with significance levels in the same order of magni-
tude as the ones obtained here. These matching strategies
might however be of interest as they could allow the ana-
lysis of more heterogeneous samples by including for
example those non-European RegiSCAR cases that were
excluded here and matching them to individuals from
the CEPH-Human Genome Diversity Panel [49].
Conclusion
Our study confirms the involvement of genetic variants
located in the HLA region in the susceptibility to SJS/
TEN in European samples, especially in association with
allopurinol. No difference is seen depending on the dis-
ease severity and no other locus reaches genome-wide
association in this sample that is also the largest one
collected so far.
Additional material
Additional file 1: Supporting material for manuscript “Genome-
Wide Association study of Stevens-Johnson Syndrome and Toxic
Epidermal Necrolysis in Europe” Results of association tests for the
top SNP (Table S1) and for the most associated haplotype (Table
S2) after stratification on the country of origin.
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